Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis

Little is known about the risk of recurrence >5 years after diagnosis among older breast cancer survivors. A community-based population of women ≥65 years diagnosed with early-stage breast cancer who survived disease free for 5 years was followed for 5 additional years or until a diagnosis of breast cancer recurrence, second primary, death, or loss to follow-up. These 5-year disease-free survivors (N = 1,277) had primary breast cancers that were node negative (77%) and estrogen receptor positive or unknown (86%). Five percent (n = 61) developed a recurrence between 5 and 10 years after diagnosis: 25% local, 9.8% regional, and 66% distant. Women who were node positive [hazard ratio (HR), 3.9; 95% confidence interval (95% CI), 1.5-10], had poorly differentiated tumors (HR, 2.5; 95% CI, 0.9-6.6), or who received breast conserving surgery without radiation therapy (HR, 2.4; 95% CI, 1.0-5.8) had higher recurrence rates compared with node negative, well differentiated, and receipt of mastectomy, respectively. Not receiving adjuvant tamoxifen, compared with receiving adjuvant tamoxifen, was also positively associated with late recurrence among women with estrogen receptor–positive/unknown tumors. Although relatively few women experience a late recurrence, most recurrences present as advanced disease, which is difficult to treat in older women. This study of late recurrence emphasizes that the risk, although small, is not negligible even in this group at high risk of death due to competing causes. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2979–83)

[1]  Sarah M. Greene,et al.  Building a research consortium of large health systems: the Cancer Research Network. , 2005, Journal of the National Cancer Institute. Monographs.

[2]  R. Gelber,et al.  Meeting highlights: adjuvant therapy for primary breast cancer. , 1992, Journal of the National Cancer Institute.

[3]  T. Lash,et al.  Recurrences and second primary breast cancers in older women with initial early‐stage disease , 2007, Cancer.

[4]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[5]  Timothy L Lash,et al.  Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study , 2007, BMC medical research methodology.

[6]  S. Edge,et al.  Treatment of early-stage breast cancer. , 1999, Current problems in cancer.

[7]  E. Winer,et al.  Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Saquib,et al.  Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. , 2009, American journal of epidemiology.

[9]  K. Hess,et al.  Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse , 2003, Breast Cancer Research and Treatment.

[10]  T. Lash,et al.  Mortality impact of less-than-standard therapy in older breast cancer patients. , 2008, Journal of the American College of Surgeons.

[11]  S. Hilsenbeck,et al.  Time-dependence of hazard ratios for prognostic factors in primary breast cancer , 2004, Breast Cancer Research and Treatment.

[12]  T. Lash,et al.  Using probabilistic corrections to account for abstractor agreement in medical record reviews. , 2007, American journal of epidemiology.

[13]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[14]  Melissa Bondy,et al.  Residual risk of breast cancer recurrence 5 years after adjuvant therapy. , 2008, Journal of the National Cancer Institute.

[15]  T. Lash,et al.  Mammography surveillance and mortality in older breast cancer survivors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  NIH consensus conference. Treatment of early-stage breast cancer. , 1991, JAMA.

[17]  Vanja Dukic,et al.  Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[18]  E. Winer,et al.  Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis , 2008 .

[19]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[20]  T. Lash,et al.  Breast cancer treatment of older women in integrated health care settings. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Winer,et al.  Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. , 2008, Journal of the National Cancer Institute.

[22]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[23]  I. Tannock,et al.  Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Lash,et al.  Re: prevalence of cancer. , 1998, Journal of the National Cancer Institute.

[25]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.